Skip to main content

A hematology clinical trial - ALC7

Testing for biomarkers to match people with myeloid cancer to myeloMATCH clinical trials for treatment
Disease Site
Hematologic Clinical Trials
Trial Code
ALC.7 (MYELOMATCH) ǀ NCT05564390
Trial Status
Open to patient enrollment
esting for Biomarkers to Match People with Myeloid Cancer to myeloMATCH Clinical Trials for Treatment

What is the purpose of this study?

This trial is the first step in joining a large research study called myeloMATCH. In myeloMATCH, researchers will conduct many different clinical trials for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

This trial is a screening study. It uses biomarker testing to tell the study doctors if they can match you with a myeloMATCH clinical trial for cancer treatment.

A biomarker (sometimes called a marker) is anything about the body that can be measured. In cancer care, specific proteins, genes, and abnormal changes in genes can be important biomarkers. Testing for certain markers can give doctors more information about each patient’s cancer and how to treat it.

Why is this study important?

The myeloMATCH study is designed to help people access new drugs in clinical trials at all stages of treatment. It will also test recently available drugs to compare them to existing treatments. It aims to speed up the pace of developing targeted treatments for myeloid cancers.

Who can participate in this study?

This trial is for:

  • People who have not started treatment yet for AML or MDS

This trial is not for:

  • People who will need treatment for another cancer while they start treatment for AML or MDS
What are the risks?
  • If you choose to take part in this study, there is a risk that:
    • You may need to have additional bone marrow draws which have risks of bleeding, bruising, infection, and pain at the biopsy site
    • There is a chance of false positive or false negative biomarker results.
    • There may not be a myeloMATCH treatment substudy available for you. If there is no available treatment substudy, you may be assigned to receive standard of care treatment and still take part in the myeloMATCH research study.
  • You will find more details of all risks in the consent document.
What can I expect?
  • If you choose to take part in this study, researchers will test your bone marrow and blood for specific biomarkers. It will take about 3 days to get your biomarker test results.
  • If there is a treatment trial that matches your biomarkers, you can choose whether to join that trial.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an Informed Consent document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The ALC7 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit https://clinicaltrials.gov/search?cond=NCT05564390

For more information about myeloMATCH >

Use this trial information for your conversation with your health care team

Participating centres
  • The Jewish General Hospital - Montreal, QC, H3T 1E2 - Contact: Dr. Sarit Assouline
  • CancerCare Manitoba - Winnipeg, MB, R3E 0V9 - Contact: Dr. Brett L. Houston
  • Arthur J.E. Child Comprehensive Cancer Centre - Calgary, AB, T2N 5G2 - Contact: Dr. Mary Lynn Savoie